Fennec Pharmaceuticals Inc.: updates and filings

FENCNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$13.45

November 19, 2026Market cap $464M

What Ploutos Investor adds for Fennec Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 14 fiscal years, from 2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($10.90 then, $13.33 on Nov 18, 2026). The figures date from before that move.10-Q
  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 85 daysAround Feb 12, 2027 · for Q4 2026

last Mar 24, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 27, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 19, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 17, 2026Other material events
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 11, 2026Shares registered for employees
    FormS-8
  • Jun 10, 2026Shareholder vote
    Form8-K
  • May 22, 2026Other material events
    Form8-K
  • May 18, 2026Officer or director change
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 28, 2026Officer or director change
    Form8-K
  • Apr 28, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 28, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 22, 2026Other material events
    Form8-K
  • Apr 7, 2026Other material events
    Form8-K
  • Mar 27, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 24, 2026Results of operations
    Form8-K
  • Mar 16, 2026Other material events
    Form8-K
  • Mar 5, 2026Shares registered for employees
    FormS-8

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 10, 2002.

The full analysis

What do Fennec Pharmaceuticals's filings show?

The filings are where every one of Fennec Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.